Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
The Company has previously announced multiple issued patents within the same patent family in the United States (U.S.).
- The Company has previously announced multiple issued patents within the same patent family in the United States (U.S.).
- "Elements of this vaccine platform have been utilized in our ricin toxin, filovirus and COVID-19 vaccine candidates, indicating its broad applicability.
- We continue to focus on vaccine development against Sudan ebolavirus and Marburg marburgvirus where there are currently no available vaccines."
- The thermostabilized filovirus vaccine program has been supported by a National Institute of Health (NIH) grant R01-AI132323 (awarded to the University of Hawaii) and a Small Business Innovation Research grant (#1R44AI157593-01; awarded to Soligenix).